Highest-materiality recent filing
TOI secures $75M OrbiMed term loan, repays $86M Deerfield convertible note
$75M term loan from OrbiMed, matures 2031, interest at SOFR+5.75% (floor 3%).
Elected eight directors: Brad Hively, Karen Johnson, Mohit Kaushal, Anne McGeorge, Mark Pacala, Mark Stolper, Kimberly Tzoumakas, Daniel Virnich.
Oncology Institute patient data accessed in Vendor cybersecurity incident; operations sustained
On May 20, 2026, Kroll notified TOI that its Vendor detected unauthorized access to TOI patient data systems.
TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M
Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.
Oncology Institute furnishes investor presentation; no material financial updates disclosed
Presentation provided for investor meetings; no earnings or guidance changes.
Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M
Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).
The Oncology Institute appoints Kim Tzoumakas to Board of Directors
Appointed Kim Tzoumakas, CEO of VytlOne National Pharmacy Services, to board effective Feb. 23, 2026.
2026 revenue guidance $630M-$650M, ~28% growth from 2025 midpoint.
TOI appoints Mark Stolper to Board as Audit Committee Chairman
Mark D. Stolper appointed to Board effective Jan 2, 2026; fills a vacancy.
Board member Gabe Ling resigns from The Oncology Institute board effective Dec 1, 2025
Gabriel Ling resigned from the Board of Directors, effective December 1, 2025, with no disagreement with the company.
Oncology Institute provides investor presentation with no specific new financial disclosures
Investor presentation furnished under Regulation FD on November 14, 2025.
TOI Q3 revenue $136.6M (+37% YoY); adjusted loss narrows, raises FY 2025 guidance
Consolidated revenue $136.6M (+36.7% YoY); gross profit $18.9M (+31.7%); net loss $(16.5)M vs $(16.1)M.
Oncology Institute discloses cyber incident impacting fee-for-service collections
Cybersecurity incident at IT software provider may cause brief immaterial delay in fee-for-service collections.
Richard Barasch retires as Chairman of The Oncology Institute; Anne McGeorge appointed as new Chair
Richard Barasch retired as Chairman effective Aug 12, 2025; no disagreement with company.
TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance
Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.
Oncology Institute explores potential PIPE financing as disclosed in investor presentation
The company is considering a private placement (PIPE) of securities according to the investor presentation cover.
TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance
Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.
TOI shareholders approve reverse stock split up to 1:40; re-elect all 8 directors
Reverse stock split approved at ratio between 1:5 and 1:40, board discretion within one year.
The Oncology Institute COO Jeremy Castle resigns effective May 30, 2025
Jeremy Castle provided notice of resignation as COO, effective May 30, 2025.
Oncology Institute regains Nasdaq minimum bid price compliance
Received Nasdaq notice on Apr 9, 2025 that closing bid was $1.00+ for 12 consecutive days through Apr 8.
The Oncology Institute closes ~$16.4M private placement and $4.1M note exchange
Private placement of 12.0M shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.
The Oncology Institute raises $16.5M via private placement and exchanges $4.1M notes
Gross proceeds of ~$16.5M from issuing 12.0M common shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.
TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M
Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.
The Oncology Institute exploring PIPE financing; investor presentation filed March 24
Filing on March 24, 2025 discloses investor presentation dated February 2025 for a potential PIPE financing.
TOI amends Deerfield credit agreement, removes $40M cash covenant, pays down $20M notes
Deerfield waived restrictions on equity issuance and removed the $40M minimum cash covenant.
Nasdaq grants TOI additional 180 days to meet $1 minimum bid price through June 16, 2025
Received Second Nasdaq Bid Price Letter on Dec 19, 2024 granting extension to June 16, 2025.
TOI Q3 revenue up 22% to $99.9M; net loss narrows to $16.1M, adjusted EBITDA -$8.2M
Revenue $99.9M (+21.8% YoY), driven by dispensary revenue surge of 79.9%.
Director Maeve O'Meara resigns effective Jan 1, 2025; Gabriel Ling to become independent director
Maeve O'Meara notified board of her resignation as director for personal reasons, effective January 1, 2025.
TOI CFO Mihir Shah resigns; Rob Carter promoted to CFO effective Oct 14
CFO Mihir Shah resigns effective October 14, 2024, to pursue other opportunities; departure not related to operations or accounting policies.
TOI reports Q2 revenue $99M (+23% YoY), net loss $15.5M; exploring strategic alternatives
Q2 revenue $99M (+22.9% YoY); net loss $15.5M vs $16.9M prior year; EPS ($0.17).
The Oncology Institute receives Nasdaq bid price deficiency notice; stock below $1.00 for 30 days
Nasdaq notice on June 20, 2024 for non-compliance with minimum bid price rule 5550(a)(2).
Shareholders approve issuance of up to 20.46M shares in Deerfield convertible notes and warrants
All nine director nominees elected with strong support; broker non-votes of ~12.2M shares.
Oncology Institute Q1 revenue up 24% to $95M; net loss narrows to $19.9M
Revenue of $95M (+24.2% YoY); net loss $19.9M vs $30.0M loss in prior year.
Oncology Institute issues FY2023 results slide presentation; no specific figures in filing excerpt
Presentation covers financial results for Q4 and full year ended Dec 31, 2023.
TOI reports Q4 revenue $86M (+20.1% YoY), net loss widens to $18.8M
Q4 2023 revenue $86M (+20.1% YoY); gross profit $14M (-8.0% YoY).
TOI reports Q3 revenue $82M (+26% YoY), net loss widens to $17.4M from $2.7M
Revenue $82M (+26% YoY); gross profit $16M (+23% YoY); gross margin 19.5% (down from 20.0%).
Oncology Institute regains Nasdaq minimum bid price compliance
Received Nasdaq notice on Sept 15, 2023 confirming compliance with Listing Rule 550(a)(2).
The Oncology Institute appoints Jeremy Castle as COO with $375K base salary
Jeremy N. Castle appointed COO effective September 5, 2023, replacing Matthew Miller, MD who departed June 16, 2023.
Director Ravi Sarin resigns from The Oncology Institute board; no disagreement cited
Ravi Sarin resigned from the Board on August 31, 2023, effective immediately.
Oncology Institute authorizes up to 2M share repurchase at ≤$1.00; Deerfield consents
Board approved repurchase of up to 2M shares of common stock at price not exceeding $1.00 per share.
Oncology Institute releases Q2 2023 results and 2023 guidance; no specific figures in filing text
Company furnished slide presentation with Q2 and H1 2023 financial results on August 10, 2023.
TOI Q2 revenue up 32% to $80M, net loss widens to $16.9M, reaffirms FY 2023 guidance
Revenue of $80M (+32% YoY); gross profit $15M (+36%); gross margin 18.8% vs 18.3%.
The Oncology Institute shareholders elect all nine directors, ratify auditor at 2023 annual meeting
64,996,623 shares voted (~86.4% of outstanding) at June 15 annual meeting.
Oncology Institute authorizes up to 5M share buyback at ≤$0.75; obtains lender consent
Board approved repurchase of up to 5M shares of common stock at price not exceeding $0.75 per share.
The Oncology Institute names Daniel Virnich as CEO, Brad Hively becomes Vice Chairman
Brad Hively steps down as CEO effective June 30, 2023, becomes Vice Chairman.
Oncology Institute CEO Brad Hively steps down, President Daniel Virnich promoted to CEO
Brad Hively resigns as CEO effective June 30, 2023; will become Vice Chairman of the Board.
COO Matthew Miller to depart June 16, 2023; duties assumed by President Virnich
Dr. Matthew Miller terminated as COO effective June 16, 2023; severance includes 3 months base salary and healthcare.
Oncology Institute Q1 revenue $76M (+38% YoY) but net loss $30M, EBITDA loss widens
Revenue of $76M, up 38.1% YoY; gross profit $14M (18.5% margin, down from 22.3%).
Oncology Institute receives Nasdaq delisting warning over bid price below $1.00
Nasdaq notified TOI on Apr 25, 2023 of non-compliance with minimum bid price rule (5450(a)(2)).
Slide presentation furnished as Exhibit 99.1 includes financial results for Q4 and FY2022.
On May 2, 2025, Jeremy Castle provided notice of his resignation as Chief Operating Officer of The Oncology Institute, Inc. (the “Company”), effective as of May 30, 2025.
On November 8, 2024, Maeve O’Meara notified the Board of Directors of The Oncology Institute, Inc. (the “Company”) of her intention to resign as a director of the Company for personal reasons, effective as of January 1, 2025 (the “Effective Date”).
On September 20, 2024, the Company appointed Robert Carter to replace Mr. Shah as the Company’s Chief Financial Officer, with effect on October 14, 2024.
On September 19, 2024, Mihir Shah, the Chief Financial Officer, principal financial officer, and principal accounting officer of The Oncology Institute, Inc. (the “Company”), delivered a notice of resignation effective as of October 14, 2024.
On September 5, 2023, The Oncology Institute, Inc., a Delaware corporation (the “Company”), appointed Jeremy N. Castle to replace Matthew Miller, MD as the Company’s Chief Operations Officer.
Dr. Miller’s separation from the Company was effective June 16, 2023, as previously disclosed in that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2023.
On August 31, 2023, Ravi Sarin, a member of the Board of Directors (the “Board”) of The Oncology Institute, Inc. (the “Company”), resigned effective immediately as a director of the Board, including any positions held as a member of any committee of the Board.
Brad Hively will transition from his role as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”) to Vice Chair of the Board of Directors of the Company.
the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer effective as of June 30, 2023
Additionally, the Board appointed Mr. Hively to serve as Vice Chair of the Board at the Effective Time
On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).
Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer
Max materiality 0.75 · Median 0.60 · Most common event earnings